---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-24-036941"
form_type: "8-K"
ticker: "MIST"
cik: "0001408443"
company_name: "Milestone Pharmaceuticals Inc."
filed_at: "2024-03-21T23:59:59+00:00"
generated_at: "2026-06-04T09:45:33.143650+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Milestone Pharma reports Q4 net loss of $13.6M; on track to resubmit NDA for etripamil in PSVT early Q2 2024

## Summary
- Net loss of $13.6M in Q4 2023, full year net loss $59.7M; Q4 revenue was $0 (vs $3.5M in Q4 2022).
- Cash and equivalents $66M as of Dec 31, 2023; March 2024 offering raised ~$32.4M net, extending cash runway into 2026.
- Plans to resubmit NDA for etripamil in PSVT early Q2 2024 after Type A meeting with FDA resolved RTF items.
- FDA reiterated guidance for AFib-RVR Phase 3 pathway contingent on PSVT NDA approval; End of Phase 2 meeting expected mid-2024.
- R&D expense fell to $5.5M in Q4 (vs $10.6M) as Phase 3 studies completed; commercial expense rose to $5.0M (vs $2.6M) for launch prep.

## SEC filing metadata
- accession: 0001104659-24-036941
- form_type: 8-K
- ticker: MIST
- cik: 0001408443
- company_name: Milestone Pharmaceuticals Inc.
- filed_at: 2024-03-21T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1408443/000110465924036941/0001104659-24-036941-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1408443/000110465924036941/tm249389d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-24-036941
- JSON: https://secwatch.observer/filing/0001104659-24-036941.json
- Plain text: https://secwatch.observer/filing/0001104659-24-036941.txt

## Key facts
- Earnings Releases
  Milestone Pharmaceuticals Inc. reported financial results for the fourth quarter and fiscal year ended December 31, 2023.
  - Period: the fourth quarter and fiscal year ended December 31, 2023
  - Result: reported results
  source text: On March 21, 2024, Milestone Pharmaceuticals Inc. (the “Company”) issued a press release announcing its financial results for the fourth quarter and fiscal year ended December 31, 2023
  evidence_url: https://www.sec.gov/Archives/edgar/data/1408443/000110465924036941/0001104659-24-036941-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.